ALMS Envudeucitinib: 24-Point IFNGS-High Lupus Split

Alumis just told investors its lupus drug failed, and the stock is probably going to be punished for a headline that is only half the story. The Phase 2b LUMUS trial of envudeucitinib missed its primary endpoint in the overall population of 408 systemic lupus erythematosus patients. That is the fact, and it is a real miss. But the prespecified high interferon gene signature subgroup, the majority of real-world lupus patients, showed a 24-point treatment effect on the primary endpoint that Alumis says justifies a Phase 3. At $21.81 for a $2.82B market cap, the question is not whether the trial failed. It is whether the market prices the drug on the overall miss or on the subgroup signal that actually matters. The bet is that the subgroup matters more, and here is the math.

First, the precise numbers, because “missed but the subgroup looked good” means nothing without them. The LUMUS trial randomized 408 autoantibody-positive patients across three envudeucitinib doses and placebo for 48 weeks, with BICLA response at Week 48 as the primary endpoint. On that endpoint, the drug was flat: placebo hit 35.7%, while the 40mg twice-daily arm hit 41.0% for a 6.2-point delta with a p-value of 0.37. The 20mg twice-daily arm posted 42.2% (p=0.35) and 20mg once-daily posted 40.0% (p=0.50). No dose separated from placebo. On SRI-4, the secondary endpoint, the results were stronger but still mixed: 40mg twice-daily hit 52.7% versus 40.4% placebo (p=0.042), and 20mg once-daily hit 60.9% (p=0.003), while 20mg twice-daily missed at 52.1% (p=0.091). In the overall population, envudeucitinib did not clear the bar.

Now the part that saves the thesis. When Alumis split the population by interferon gene signature, the picture inverted. In IFNGS-high patients, 40mg twice-daily posted a 52.6% BICLA response versus 28.6% on placebo, a 24-point delta. On SRI-4 it was 60.9% versus 33.1%. On CLASI-50, a skin disease measure, it was 61.5% versus 25.0%, a 36-point split. In IFNGS-low patients, the drug actually lost to placebo on BICLA, 24.4% versus 47.5%. That is the story in one line: envudeucitinib does nothing in IFNGS-low lupus and a lot in IFNGS-high lupus, and the overall miss happened because LUMUS accidentally enrolled too many of the wrong patients. Every active dose beat placebo on all five key endpoints inside the IFNGS-high subgroup, which is what a real mechanism-driven effect looks like rather than a noise artifact.

That enrollment imbalance is the crucial detail, and it is why the drug is not written off. IFNGS-high patients represent roughly 70% of moderate-to-severe lupus in the real world. In LUMUS, they made up only about 60% of each arm, with roughly 40% IFNGS-low, which the company says was higher than expected. IFNGS-low patients are known to have high placebo response rates and weak responses to interferon-pathway drugs, and that is exactly what happened: the IFNGS-low placebo arm hit 47.5% BICLA, dragging the overall effect toward zero. This is a trial design flaw, not a mechanism failure. The biology is intact because TYK2 sits upstream of type I interferon signaling, and envudeucitinib is the only TYK2 inhibitor that delivers maximal target inhibition over a full 24 hours. The pharmacodynamic data confirmed dose-dependent interferon-pathway suppression, which is the evidence that the drug is hitting its target.

The competitive context is what makes the subgroup signal credible. Anifrolumab, AstraZeneca’s approved Saphnelo, validated the interferon hypothesis when TULIP-2 posted a 16.3-point BICLA delta overall (47.8% versus 31.5%, p=0.001) and a 17.3-point delta in IFNGS-high patients. Envudeucitinib’s 24-point IFNGS-high delta is actually larger than anifrolumab’s, with the obvious caveat that it is a subgroup of a Phase 2b trial versus anifrolumab’s registrational Phase 3. The other TYK2 comp is Bristol Myers’ Sotyktu, the first selective TYK2 inhibitor, which generated roughly $291M in 2025 sales in psoriasis but never produced convincing lupus data. Envudeucitinib’s claim is that its 24-hour maximal inhibition is the difference Sotyktu lacked, because Sotyktu’s shorter target coverage left a window where interferon signaling could recover. That is a hypothesis, not a fact, but it is a testable one with the Phase 3 design Alumis now controls.

The valuation setup is where the numbers get specific. Alumis at $2.82B is a pre-revenue company with a psoriasis NDA coming in Q4 2026 and a lupus program that is now optionality rather than a base case. Sotyktu took roughly four years from approval to reach $291M in annual sales, and it competes in a crowded psoriasis market against injectable biologics and Otezla. If envudeucitinib’s 24-hour coverage makes it best-in-class among oral TYK2s, a $500M to $1B peak in psoriasis is reasonable, and on a 3x to 4x peak-sales multiple that is $1.5B to $4B of value before the lupus option. The market is already crediting most of that, which is why the lupus miss matters for the margin of safety but does not collapse the thesis. The cleanest way to think about it: psoriasis is the floor, lupus is the ceiling, and the stock at $21.81 is paying for the floor with the ceiling thrown in at a discount.

The near-term catalyst has nothing to do with lupus, and that is the part the market may underweight. Alumis plans to file its NDA for envudeucitinib in plaque psoriasis in Q4 2026, backed by positive Phase 3 ONWARD data. Psoriasis is the base case; lupus is the upside. A $2.82B market cap is pricing in psoriasis approval plus a discount for the lupus miss, which is roughly right, but the selloff could overdo it because retail investors read “SLE Phase 2b failed” and assume the drug is dead. It is not. The lupus program is being repositioned, not abandoned, with an end-of-Phase 2 meeting with the FDA and EMA planned to lock the Phase 3 design around IFNGS-high enrollment.

The risk is real and specific. A Phase 2b subgroup signal does not become a Phase 3 win automatically. Enriching Phase 3 for IFNGS-high patients fixes the enrollment problem, but a biomarker-selected registrational trial is harder to run, and the FDA has historically been cautious about approving drugs on the strength of interferon-signature subgroups alone. There is also the cash question: Alumis is a pre-revenue biotech funding both a psoriasis launch and a lupus Phase 3, which means dilution risk between now and the psoriasis launch. If the psoriasis NDA slips past Q4 2026, the base case itself comes under pressure, and the stock’s $2.82B market cap is not cheap for a pre-revenue company on a 6-point overall delta. And the safety tailwind cuts both ways: envudeucitinib’s clean profile with no MACE, no malignancies, and lower adverse-event rates than placebo is a genuine asset in a field where anifrolumab carries a herpes zoster signal, but it does not remove the risk that the FDA simply wants a second well-powered confirmatory trial before acting on a biomarker subgroup.

Verdict: hold through the overreaction. The lupus program is upside with a 24-point signal in the right subgroup, and the psoriasis NDA in Q4 2026 is the real value driver that did not change today. If the stock sells off on the headline, that is the entry for a 1% position sized around the psoriasis catalyst, not the lupus readout. Do not build a full position on an IFNGS-high subgroup, but do not sell a drug that just showed a 36-point CLASI-50 split in the patients who actually matter. The broader lesson is one every biotech investor should internalize: when a trial misses overall but the prespecified biomarker subgroup is strong and the mechanism matches the biology, the miss is an enrollment problem, not a drug problem. That is exactly what separates a dead asset from a repositioned one, and it is the difference between panicking on the headline and buying the discount. For how to read a clinical press release like this one without overreacting, start with the press release guide, for the SLE competitive picture including J&J’s nipocalimab see the earlier analysis, and for the broader autoimmune catalyst calendar see the immunology catalysts roundup.